In Silico Design of Dual Estrogen Receptor and Hsp90 Inhibitors for ER-Positive Breast Cancer Through a Mixed Ligand/Structure-Based Approach
Breast cancer remains one of the most prevalent and lethal malignancies in women, particularly the estrogen receptor-positive (ER+) subtype, which accounts for approximately 70% of cases. Traditional endocrine therapies, including aromatase inhibitors, selective estrogen receptor degraders/antagonis...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/29/24/6040 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846103416039800832 |
|---|---|
| author | Gabriele La Monica Federica Alamia Alessia Bono Francesco Mingoia Annamaria Martorana Antonino Lauria |
| author_facet | Gabriele La Monica Federica Alamia Alessia Bono Francesco Mingoia Annamaria Martorana Antonino Lauria |
| author_sort | Gabriele La Monica |
| collection | DOAJ |
| description | Breast cancer remains one of the most prevalent and lethal malignancies in women, particularly the estrogen receptor-positive (ER+) subtype, which accounts for approximately 70% of cases. Traditional endocrine therapies, including aromatase inhibitors, selective estrogen receptor degraders/antagonists (SERDs), and selective estrogen receptor modulators (SERMs), have improved outcomes for metastatic ER+ breast cancer. However, resistance to these agents presents a significant challenge. This study explores a novel therapeutic strategy involving the simultaneous inhibition of the estrogen receptor (ER) and the chaperone protein Hsp90, which is crucial for the stabilization of various oncoproteins, including ER itself. We employed a hybrid, hierarchical in silico virtual screening approach to identify new dual ER/Hsp90 inhibitors, utilizing the Biotarget Predictor Tool (BPT) for efficient multitarget screening of a large compound library. Subsequent structure-based studies, including molecular docking analyses, were conducted to further evaluate the interaction of the top candidates with both ER and Hsp90. Supporting this, molecular dynamics simulations demonstrate the high stability of the multitarget inhibitor <b>755435</b> in complex with ER and Hsp90. Our findings suggest that several small molecules, particularly compound <b>755435</b>, exhibit promising potential as dual inhibitors, representing a new avenue to overcome resistance in ER+ breast cancer. |
| format | Article |
| id | doaj-art-4cfb8ece878e47dfa41af57ece68e6dd |
| institution | Kabale University |
| issn | 1420-3049 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj-art-4cfb8ece878e47dfa41af57ece68e6dd2024-12-27T14:43:01ZengMDPI AGMolecules1420-30492024-12-012924604010.3390/molecules29246040In Silico Design of Dual Estrogen Receptor and Hsp90 Inhibitors for ER-Positive Breast Cancer Through a Mixed Ligand/Structure-Based ApproachGabriele La Monica0Federica Alamia1Alessia Bono2Francesco Mingoia3Annamaria Martorana4Antonino Lauria5Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche “STEBICEF”, University of Palermo, Viale delle Scienze, Ed. 17, 90128 Palermo, ItalyDipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche “STEBICEF”, University of Palermo, Viale delle Scienze, Ed. 17, 90128 Palermo, ItalyDipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche “STEBICEF”, University of Palermo, Viale delle Scienze, Ed. 17, 90128 Palermo, ItalyIstituto per lo Studio dei Materiali Nanostrutturati, Consiglio Nazionale delle Ricerche (CNR), 90128 Palermo, ItalyDipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche “STEBICEF”, University of Palermo, Viale delle Scienze, Ed. 17, 90128 Palermo, ItalyDipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche “STEBICEF”, University of Palermo, Viale delle Scienze, Ed. 17, 90128 Palermo, ItalyBreast cancer remains one of the most prevalent and lethal malignancies in women, particularly the estrogen receptor-positive (ER+) subtype, which accounts for approximately 70% of cases. Traditional endocrine therapies, including aromatase inhibitors, selective estrogen receptor degraders/antagonists (SERDs), and selective estrogen receptor modulators (SERMs), have improved outcomes for metastatic ER+ breast cancer. However, resistance to these agents presents a significant challenge. This study explores a novel therapeutic strategy involving the simultaneous inhibition of the estrogen receptor (ER) and the chaperone protein Hsp90, which is crucial for the stabilization of various oncoproteins, including ER itself. We employed a hybrid, hierarchical in silico virtual screening approach to identify new dual ER/Hsp90 inhibitors, utilizing the Biotarget Predictor Tool (BPT) for efficient multitarget screening of a large compound library. Subsequent structure-based studies, including molecular docking analyses, were conducted to further evaluate the interaction of the top candidates with both ER and Hsp90. Supporting this, molecular dynamics simulations demonstrate the high stability of the multitarget inhibitor <b>755435</b> in complex with ER and Hsp90. Our findings suggest that several small molecules, particularly compound <b>755435</b>, exhibit promising potential as dual inhibitors, representing a new avenue to overcome resistance in ER+ breast cancer.https://www.mdpi.com/1420-3049/29/24/6040estrogen receptor (ER)Hsp90 inhibitionendocrine resistancemultitarget drug designDRUDITNCI database |
| spellingShingle | Gabriele La Monica Federica Alamia Alessia Bono Francesco Mingoia Annamaria Martorana Antonino Lauria In Silico Design of Dual Estrogen Receptor and Hsp90 Inhibitors for ER-Positive Breast Cancer Through a Mixed Ligand/Structure-Based Approach Molecules estrogen receptor (ER) Hsp90 inhibition endocrine resistance multitarget drug design DRUDIT NCI database |
| title | In Silico Design of Dual Estrogen Receptor and Hsp90 Inhibitors for ER-Positive Breast Cancer Through a Mixed Ligand/Structure-Based Approach |
| title_full | In Silico Design of Dual Estrogen Receptor and Hsp90 Inhibitors for ER-Positive Breast Cancer Through a Mixed Ligand/Structure-Based Approach |
| title_fullStr | In Silico Design of Dual Estrogen Receptor and Hsp90 Inhibitors for ER-Positive Breast Cancer Through a Mixed Ligand/Structure-Based Approach |
| title_full_unstemmed | In Silico Design of Dual Estrogen Receptor and Hsp90 Inhibitors for ER-Positive Breast Cancer Through a Mixed Ligand/Structure-Based Approach |
| title_short | In Silico Design of Dual Estrogen Receptor and Hsp90 Inhibitors for ER-Positive Breast Cancer Through a Mixed Ligand/Structure-Based Approach |
| title_sort | in silico design of dual estrogen receptor and hsp90 inhibitors for er positive breast cancer through a mixed ligand structure based approach |
| topic | estrogen receptor (ER) Hsp90 inhibition endocrine resistance multitarget drug design DRUDIT NCI database |
| url | https://www.mdpi.com/1420-3049/29/24/6040 |
| work_keys_str_mv | AT gabrielelamonica insilicodesignofdualestrogenreceptorandhsp90inhibitorsforerpositivebreastcancerthroughamixedligandstructurebasedapproach AT federicaalamia insilicodesignofdualestrogenreceptorandhsp90inhibitorsforerpositivebreastcancerthroughamixedligandstructurebasedapproach AT alessiabono insilicodesignofdualestrogenreceptorandhsp90inhibitorsforerpositivebreastcancerthroughamixedligandstructurebasedapproach AT francescomingoia insilicodesignofdualestrogenreceptorandhsp90inhibitorsforerpositivebreastcancerthroughamixedligandstructurebasedapproach AT annamariamartorana insilicodesignofdualestrogenreceptorandhsp90inhibitorsforerpositivebreastcancerthroughamixedligandstructurebasedapproach AT antoninolauria insilicodesignofdualestrogenreceptorandhsp90inhibitorsforerpositivebreastcancerthroughamixedligandstructurebasedapproach |